SCHEMBL6929649

SCHEMBL6929649

O=Nc1ccc(Nc2cccc3ccccc23)c2ccccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25B P30305 2/20 0.50
CYP3A4 P08684 2/20 0.50
HSD17B10 Q99714 2/20 0.50
ALDH1A1 P00352 2/20 0.50
TP53 P04637 1/20 0.50
HPGD P15428 1/20 0.50
ALOX15 P16050 1/20 0.50
TSHR P16473 1/20 0.50
ATM Q13315 1/20 0.50
KDM4E B2RXH2 4/20 0.43
GAA P10253 3/20 0.43
FADS1 O60427 1/20 0.42
CDC25A P30304 1/20 0.42
CDC25C P30307 1/20 0.42
KEAP1 Q14145 1/20 0.42
RAB9A P51151 2/20 0.41
MAPT P10636 4/20 0.41
RECQL P46063 2/20 0.41
MEN1 O00255 1/20 0.41
GLA P06280 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL49213 0.79 HSD17B10 (0.74) CDC25BCYP3A4HSD17B10ALDH1A1TP53
SCHEMBL8966295 0.79 TDP1 (0.59) CDC25BCYP3A4HSD17B10ALDH1A1TP53
Ammonia Solution, Strong SCHEMBL11586421 0.77 HSD17B10 (0.71) CDC25BCYP3A4HSD17B10ALDH1A1TP53
SCHEMBL8500339 0.77 HSD17B10 (0.71) CDC25BCYP3A4HSD17B10ALDH1A1TP53
SCHEMBL1921580 0.77 HSD17B10 (0.71) CDC25BCYP3A4HSD17B10ALDH1A1TP53
SCHEMBL2933245 0.75 ALDH1A1 (0.54) CYP3A4HSD17B10ALDH1A1HPGDALOX15
SCHEMBL31126043 0.75 ALDH1A1 (0.54) CYP3A4HSD17B10ALDH1A1HPGDALOX15
SCHEMBL1275295 0.74 ALDH1A1 (0.47) CYP3A4HSD17B10ALDH1A1TP53HPGD
SCHEMBL20033073 0.74 HSD17B10 (0.57) CDC25BCYP3A4HSD17B10ALDH1A1TP53
SCHEMBL21645599 0.74 HPRT1 (0.61) CDC25BCYP3A4HSD17B10ALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107810204-B Composition for immediate termination of free radical polymerization 巴斯夫欧洲公司 2020-04-14 CN disclosed
EP-3310819-B1 COMPOSITION FOR IMMEDIATELY ENDING RADICAL POLYMERIZATION BASF SE (DE) 2019-06-12 EP disclosed
US-10221255-B2 Composition for the immediate stopping of a free-radical polymerization BASF SE (DE) 2019-03-05 US disclosed
US-20180171035-A1 COMPOSITION FOR THE IMMEDIATE STOPPING OF A FREE-RADICAL POLYMERIZATION BASF SE (DE) 2018-06-21 US disclosed
EP-3310819-A1 COMPOSITION FOR IMMEDIATELY ENDING RADICAL POLYMERIZATION BASF SE (DE) 2018-04-25 EP disclosed
CN-107810204-A For terminating the composition of radical polymerization immediately 巴斯夫欧洲公司 2018-03-16 CN disclosed
WO-2016202883-A1 COMPOSITION FOR IMMEDIATELY ENDING RADICAL POLYMERIZATION BASF SE (DE) 2016-12-22 WO disclosed
US-6518452-B1 A method of stabilizing an ester of (meth)acrylic acid against free-radical polymerization, comprising: adding to said ester of (meth)acrylic acid a polymerization inhibitor which comprises at least one nitroxyl radical and/or at least BASF AKTIENGESELLSCHAFT (DE) 2003-02-11 US disclosed
US-6518374-B1 Inhibitor solution, containing at least 10% phenothiazine, from 5 to 10% p-methoxyphenol and at least 50% N-methylpyrrolidone BASF AKTIENGESELLSCHAFT (DE) 2003-02-11 US disclosed
EP-1177218-B1 METHOD OF IMMEDIATELY TERMINATING FREE-RADICAL POLYMERISATION PROCESSES BASF AG (DE) 2002-12-11 EP disclosed
EP-1177218-A1 METHOD OF IMMEDIATELY TERMINATING FREE-RADICAL POLYMERISATION PROCESSES BASF AKTIENGESELLSCHAFT (DE) 2002-02-06 EP disclosed
US-H1957-H1 ADDING A PHENOTHIAZINE-CONTAINING SOLUTION WHOSE SOLVENT COMPRISES AT LEAST 50% OF ITS WEIGHT OF AN N-ALKYLPYRROLIDONE BASF AKTIENGESELLSCHAFT (DE) 2001-04-03 US disclosed
WO-2000064947-A1 METHOD OF IMMEDIATELY TERMINATING FREE-RADICAL POLYMERISATION PROCESSES BASF AKTIENGESELLSCHAFT (DE) 2000-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10221255-B2 Composition for the immediate stopping of a free-radical polymerization FASTKD5, TYK2, FASTKD1 CDC25B 565/4885CYP3A4 481/4885HSD17B10 1997/4885
US-20180171035-A1 COMPOSITION FOR THE IMMEDIATE STOPPING OF A FREE-RADICAL POLYMERIZATION FASTKD5, TYK2, FASTKD1 CDC25B 565/4885CYP3A4 481/4885HSD17B10 1997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.